UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
23,18 € ↑0,82 (3,67%)
2026-06-05
DEL PRIS
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionMorgan Stanley
Latest Disclosed Ownership2,488,299 shares
Ownership 5.40%
Morgan Stanley ownership in UR8 / UroGen Pharma Ltd.

2025-08-06 - Morgan Stanley has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,488,299 shares of UroGen Pharma Ltd. (DE:UR8). This represents 5.4 percent ownership of the company. In their previous filing dated 2025-02-05 , Morgan Stanley had reported owning 752,861 shares, indicating an increase of 230.51 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-08-06 2025-08-06 13G 752,861 2,488,299 230.51 5.40 200.00
2025-02-05 2025-02-05 13G/A 2,172,327 752,861 -65.34 1.80 -65.38
2024-11-06 2024-11-06 13G 2,172,327 5.20

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F UROGEN PHARMA COM M96088105 2,560,038 -2,863 -0.11 46,029 -23.31 0.0028
2026-05-27 2025-12-31 13F/A-1 UROGEN PHARMA COM M96088105 2,562,901 34,455 1.36 60,023 18.99 0.0036
2026-02-13 2025-12-31 13F UROGEN PHARMA COM M96088105 2,562,901 34,455 60,023
2026-05-27 2025-09-30 13F/A-1 UROGEN PHARMA COM M96088105 2,528,446 49,976 2.02 50,442 48.56 0.0031
2025-11-14 2025-09-30 13F UROGEN PHARMA COM M96088105 2,528,446 49,976 50,442 0.0031
2025-08-15 2025-06-30 13F UROGEN PHARMA COM M96088105 2,478,470 1,620,743 188.96 33,955 257.95 0.0022
2025-05-15 2025-03-31 13F UROGEN PHARMA COM M96088105 857,727 90,427 11.79 9,486 16.09 0.0007
2025-05-15 2024-12-31 13F/A-1 UROGEN PHARMA COM M96088105 767,300 -1,414,164 -64.83 8,172 -70.51 0.0006
2025-02-14 2024-12-31 13F UROGEN PHARMA COM M96088105 767,300 -1,414,164 8,172 0.0006
2025-05-14 2024-09-30 13F/A-2 UROGEN PHARMA COM M96088105 2,181,464 342,758 18.64 27,705 -10.21 0.0020
2025-02-14 2024-09-30 13F/A-1 UROGEN PHARMA COM M96088105 2,181,464 342,758 27,705 0.0020
2024-11-14 2024-09-30 13F UROGEN PHARMA COM M96088105 2,181,464 342,758 27,705 0.0020
2025-05-14 2024-06-30 13F/A-2 UROGEN PHARMA COM M96088105 1,838,706 1,448,157 370.80 30,853 426.68 0.0024
2024-10-17 2024-06-30 13F/A-1 UROGEN PHARMA COM M96088105 1,838,706 1,448,157 30,853 0.0024
2024-08-14 2024-06-30 13F UROGEN PHARMA COM M96088105 1,838,706 1,448,157 30,853 0.0024
2024-10-17 2024-03-31 13F/A-2 UROGEN PHARMA COM M96088105 390,549 -64,575 -14.19 5,858 -14.18 0.0005
2024-08-16 2024-03-31 13F/A-1 UROGEN PHARMA COM M96088105 390,549 -64,575 5,858 0.0005
2024-05-15 2024-03-31 13F UROGEN PHARMA COM M96088105 390,549 -64,575 5,858 0.0005
2024-08-16 2023-12-31 13F/A-1 UROGEN PHARMA COM M96088105 455,124 343,997 309.55 6,827 338.69 0.0006
2024-02-13 2023-12-31 13F UROGEN PHARMA COM M96088105 455,124 343,997 6,827 0.0006
2023-11-15 2023-09-30 13F UROGEN PHARMA COM M96088105 111,127 48,174 76.52 1,557 139.02 0.0002
2023-08-14 2023-06-30 13F UROGEN PHARMA COM M96088105 62,953 -80,506 -56.12 652 -50.87 0.0001
2023-05-15 2023-03-31 13F UROGEN PHARMA COM M96088105 143,459 94,310 191.89 1,326 204.60 0.0001
2023-02-14 2022-12-31 13F UROGEN PHARMA COM M96088105 49,149 4,139 9.20 436 15.69 0.0000
2022-11-14 2022-09-30 13F UROGEN PHARMA COM M96088105 45,010 -38,266 -45.95 376 -44.79 0.0001
2022-10-27 2022-06-30 13F/A-1 UROGEN PHARMA COM M96088105 83,276 43,383 108.75 681 95.13 0.0001
2022-08-15 2022-06-30 13F UROGEN PHARMA COM M96088105 83,276 43,383 681 0.0001
2022-10-27 2022-03-31 13F/A-1 UROGEN PHARMA COM M96088105 39,893 17,519 78.30 349 63.08 0.0000
2022-05-13 2022-03-31 13F UROGEN PHARMA COM M96088105 39,893 17,519 349 0.0000
2022-02-14 2021-12-31 13F UROGEN PHARMA COM M96088105 22,374 -21,329 -48.80 214 -70.84 0.0000
2021-11-15 2021-09-30 13F UROGEN PHARMA COM M96088105 43,703 -29,897 -40.62 734 -34.76 0.0001
2021-08-23 2021-06-30 13F/A-1 UROGEN PHARMA COM M96088105 73,600 72,367 5,869.18 1,125 4,587.50 0.0001
2021-08-16 2021-06-30 13F UROGEN PHARMA COM M96088105 73,600 72,367 1,125 0.0000
2021-05-17 2021-03-31 13F UROGEN PHARMA COM M96088105 1,233 -15,945 -92.82 24 -92.26 0.0000
2021-02-16 2020-12-31 13F UROGEN PHARMA COM M96088105 17,178 13,495 366.41 310 336.62 0.0000
2020-11-13 2020-09-30 13F UROGEN PHARMA COM M96088105 3,683 -87,348 -95.95 71 -97.01 0.0000
2020-08-14 2020-06-30 13F UROGEN PHARMA COM M96088105 91,031 87,825 2,739.39 2,377 4,070.18 0.0005
2020-05-26 2020-03-31 13F/A-1 UROGEN PHARMA COM M96088105 3,206 -24,803 -88.55 57 -93.90 0.0000
2020-05-15 2020-03-31 13F UROGEN PHARMA COM M96088105 3,206 -24,803 57 4.3788
2020-02-14 2019-12-31 13F UROGEN PHARMA COM M96088105 28,009 17,832 175.22 935 286.36 0.0002
2019-11-14 2019-09-30 13F UROGEN PHARMA COM M96088105 10,177 4,759 87.84 242 24.74 0.0001
2019-08-14 2019-06-30 13F UROGEN PHARMA COM M96088105 5,418 -19,505 -78.26 194 -78.91 0.0001
2019-05-15 2019-03-31 13F UROGEN PHARMA COM M96088105 24,923 9,856 65.41 920 41.76 0.0003
2019-02-14 2018-12-31 13F UROGEN PHARMA COM M96088105 15,067 -14,823 -49.59 649 -54.04 0.0002
2019-04-23 2018-09-30 13F/A-2 UROGEN PHARMA COM M96088105 29,890 -6,155 -17.08 1,412 -21.29 0.0004
2018-11-20 2018-09-30 13F/A-1 UROGEN PHARMA COM M96088105 29,890 0 1,412 0.0004
2018-11-14 2018-09-30 13F UROGEN PHARMA COM M96088105 29,890 -6,155 1,412
2019-04-23 2018-06-30 13F/A-1 UROGEN PHARMA COM M96088105 36,045 7,188 24.91 1,794 25.10 0.0005
2018-08-14 2018-06-30 13F UROGEN PHARMA COM M96088105 36,045 7,188 1,794
2019-04-23 2018-03-31 13F/A-1 UROGEN PHARMA COM M96088105 28,857 -4,555 -13.63 1,434 15.37 0.0004
2018-05-14 2018-03-31 13F UROGEN PHARMA COM M96088105 28,857 -4,555 1,434
2019-04-23 2017-12-31 13F/A-1 UROGEN PHARMA COM M96088105 33,412 9,756 41.24 1,243 66.62 0.0003
2018-02-14 2017-12-31 13F UROGEN PHARMA COM M96088105 33,412 9,756 1,243
2017-11-14 2017-09-30 13F UROGEN PHARMA COM M96088105 23,656 23,656 746 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.